Licensing · MENA · Announced 8 May 2025
Kashiv BioSciences → MS Pharma
Licensing deal between Kashiv BioSciences (United States) and MS Pharma (Saudi Arabia), covering Omalizumab, announced 8 May 2025. Value: Undisclosed.
Parties: Kashiv BioSciences, LLC (United States) → MS PHARMA (Saudi Arabia)
- Deal type
- Licensing
- Value
- Undisclosed
- Territory
- MENA (Saudi Arabia as the potential local-manufacturing base; broader-MENA commercialization)
- Therapeutic area
- Immunology / Inflammation
- Asset
- Omalizumab
- Announced
- 8 May 2025
Our analysis
Why this matters.
In August 2025, US biosimilar developer Kashiv BioSciences licensed MENA rights for ADL-018 — its proposed biosimilar to Xolair (omalizumab) , Roche/Novartis's anti-IgE blockbuster for chronic urticaria, allergic asthma, nasal polyps and food allergy — to MS Pharma , a leading MENA regional pharma.
The full analysis is free to read with a work email on this page.
Source: BusinessWire